Yingjiexin raises $30M Series B to scale drug-delivery devices globally
What's the deal? Shanghai Yingjiexin Medical TechnologyDealroom has a profile for this one. Try Dealroom → has raised US$27.5M in a Series B round, the company announced in November 2026. CICC Capital led the round, with participation from Zhuhai Technology Industry Group, Cornerstone CapitalDealroom has a profile for this one. Try Dealroom →, Qiming Venture Partners, Houxin Jiantou, and Yingyue Fund; existing backer Photon Venture Capital reinvested.
What's the endgame? Yingjiexin develops and manufactures high-precision drug-delivery devices — including disposable prefilled pens, reusable injection pens, and autoinjectors — for biologics such as GLP-1 drugs, insulin, and growth hormone. The new capital will fund expanded production, research into a next-generation self-administration device, and overseas product registration.
Why now? The round extends an existing scale-up path rather than marking a change in direction. Yingjiexin closed a Series A in 2024 and a Series A+ in 2025, both earmarked for capacity building and international expansion.
What's the bigger picture? The company says its injection pens have annual capacity above 150 million units but did not disclose output, utilisation, or revenue. Demand for pens and autoinjectors is rising as biologics like GLP-1 and insulin require matching delivery devices, lifting drugmakers' need for reliable mass production.
What could go wrong? Device makers' actual volumes still hinge on customers' drug approvals and order flow. Without disclosed orders, utilisation rates, or progress on overseas registration, the raise cannot be read as commercial success on its own.
The signal: Competition in the sector is about more than capacity, as drugmakers' tie-ups with established suppliers show — Uni-Bio, for one, is working with YpsomedDealroom has a profile for this one. Try Dealroom → on prefilled pens for GLP-1 products. For Yingjiexin, the notable element is investor backing and the intent to expand global delivery.
Read more: sohu.com
Image credit: Generated with Gemini
